Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.

Revenue projections:

Revenue projections for DIVISLAB
Revenue projections for DIVISLAB

Investors may react cautiously to news that DIVISLAB's revenues are forecasted to be lower than last year's. Such declines are likely to have a negative effect on the company's bottom line, which can lead to concerns about profitability and hinder investor confidence in the company's future performance.

Financial Ratios:

currentRatio 5.696000
forwardPE 50.285873
debtToEquity 0.584000
earningsGrowth 0.353000
revenueGrowth 0.161000
grossMargins 0.607940
operatingMargins 0.285450
trailingEps 93.780000
forwardEps 119.546500

Divi's Laboratories Limited's current ratio being 5.696 suggests that the company has no issue servicing its short-term debt. Its strong liquidity position, supported by sufficient cash reserves and current assets, ensures that Divi's Laboratories Limited can meet its financial obligations with ease.
With DIVISLAB's forward PE ratio being elevated, the stock may see limited price appreciation and face correction risks. It's essential to assess this metric alongside other fundamentals to determine the sustainability of the stock's current valuation.
DIVISLAB's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that DIVISLAB will continue to grow its operations, driven by increasing profits and revenue.
Divi's Laboratories Limited's positive gross and operating margins suggest the company is performing profitably. These margins reflect efficient cost management and strong revenue generation, signaling healthy financial performance and operational effectiveness.
Divi's Laboratories Limited's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that Divi's Laboratories Limited is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for DIVISLAB
Price projections for DIVISLAB

Over time, price projections for DIVISLAB have gradually increased, reflecting rising confidence in the company's future performance. This upward trend suggests analysts expect DIVISLAB to continue on a positive growth trajectory.

Insider Transactions:

Insider Transactions for DIVISLAB
Insider Transactions for DIVISLAB


DIVISLAB saw 10 transactions in which shares were sold with market price at 6352.37001953125.1 buy transactions of DIVISLAB stock were completed, with market price at 5959.64990234375.The trend of more buys than sells at DIVISLAB's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.

Recommendation changes over time:

Recommendations trend for DIVISLAB
Recommendations trend for DIVISLAB


A recent buy bias from analysts toward Divi's Laboratories Limited indicates strong confidence in the stock's future performance. This could encourage investors to park their money in Divi's Laboratories Limited, viewing it as a stable and potentially rewarding investment opportunity with promising long-term growth prospects.